Immunoglobulin News and Research

RSS
SARS-CoV-2 immune memory in mRNA vaccine recipients

SARS-CoV-2 immune memory in mRNA vaccine recipients

Scientists identify molecular features of antibody responses to SARS-CoV-2 spike

Scientists identify molecular features of antibody responses to SARS-CoV-2 spike

A case of post-vaccination MIS in an adult without prior SARS-CoV-2 infection

A case of post-vaccination MIS in an adult without prior SARS-CoV-2 infection

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

Pediatric COVID-19 and PIMS-TS: hospitalization, severe disease and mortality risk

Pediatric COVID-19 and PIMS-TS: hospitalization, severe disease and mortality risk

Link between tobacco product use and alcohol consumption with anti-SARS-CoV-2 antibody titers after BNT162b2 vaccine

Link between tobacco product use and alcohol consumption with anti-SARS-CoV-2 antibody titers after BNT162b2 vaccine

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

Impact of SARS-CoV-2 on oral health

Impact of SARS-CoV-2 on oral health

Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection

Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection

Immunity found 6 months after SARS-CoV-2 infection in children

Immunity found 6 months after SARS-CoV-2 infection in children

Do we need COVID-19 vaccine boosters?

Do we need COVID-19 vaccine boosters?

Low neutralizing antibody titers against SARS-CoV-2 Mu in BNT162b2 vaccinated

Low neutralizing antibody titers against SARS-CoV-2 Mu in BNT162b2 vaccinated

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

Study explores adverse effects of SARS-CoV-2-induced antibody responses

Study explores adverse effects of SARS-CoV-2-induced antibody responses

COVID-19 vaccine boosters to prevent breakthrough SARS-CoV-2 infections in healthy adults

COVID-19 vaccine boosters to prevent breakthrough SARS-CoV-2 infections in healthy adults

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.